Anaemia management in people with chronic kidney disease
This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/cg114
About this guideline
NICE clinical guidelines are recommendations about the treatment and care of people with specific diseases and conditions in the NHS in England and Wales.
The guideline was developed by the National Clinical Guideline Centre. The Centre worked with a group of healthcare professionals (including consultants, GPs and nurses), patients and carers, and technical staff, who reviewed the evidence and drafted the recommendations. The recommendations were finalised after public consultation.
The methods and processes for developing NICE clinical guidelines are described in The guidelines manual.
This guideline updates and replaces NICE clinical guideline 30 (published 2006).
The recommendations from this guideline have been incorporated into a NICE Pathway. We have produced information for the public explaining this guideline. Tools to help you put the guideline into practice and information about the evidence it is based on are also available.
Changes after publication
New recommendations have been added for the diagnostic evaluation and assessment of anaemia and the assessment and optimisation of erythropoiesis.
Recommendations are marked as , [2006, amended 2011] or [new 2011].
 indicates that the evidence has not been updated and reviewed since 2006.
[2006, amended 2011] indicates recommendations where the evidence has not been reviewed since the original guideline but they have been amended because of GDG consensus that they no longer reflect clinical practice or to add clarity; or recommendations that need amending to be consistent with new recommendations.
January 2012: minor maintenance
May 2013: minor maintenance
This guidance represents the view of NICE, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, and informed by the summary of product characteristics of any drugs they are considering.
Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
© National Institute for Health and Clinical Excellence 2011. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.
National Institute for Health and Clinical Excellence
Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT